Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Thomas Civik Biography and Net Worth

Director of Pyxis Oncology

Mr. Thomas Civik most recently served as President and Chief Executive Officer of Five Prime Therapeutics until its acquisition by Amgen for $1.9 billion in April 2021. He was previously Chief Commercial Officer at Foundation Medicine, delivering significant growth during his tenure and launching the first ever FDA-approved pan-cancer comprehensive genomic test.

He held various roles over a 17-year career at Genentech, including responsibility for several important therapies such as Avastin, Tecentriq, Alecensa and Tarceva. Mr. Civik earned a B.A. from St. Norbert College, and an M.B.A. from Northwestern University Kellogg School of Management.

How do I contact Thomas Civik?: The corporate mailing address for Mr. Civik and other Pyxis Oncology executives is , , . Pyxis Oncology can also be reached via phone at 617-221-9059 and via email at [email protected]. Learn More on Thomas Civik's contact information.
Has Thomas Civik been buying or selling shares of Pyxis Oncology?: Thomas Civik has not been actively trading shares of Pyxis Oncology in the last ninety days. Most recently, on Thursday, November 18th, Thomas Civik bought 15,700 shares of Pyxis Oncology stock. The stock was acquired at an average cost of $12.74 per share, with a total value of $200,018.00. Learn More on Thomas Civik's trading history.
Who are Pyxis Oncology's active insiders?: Pyxis Oncology's insider roster includes Thomas Civik (Director), and Darren Cline (Director). Learn More on Pyxis Oncology's active insiders.
Are insiders buying or selling shares of Pyxis Oncology?: During the last twelve months, Pyxis Oncology insiders bought shares 6 times. They purchased a total of 33,426 shares worth more than $58,503.10. During the last twelve months, insiders at the sold shares 3 times. They sold a total of 31,541 shares worth more than $70,146.10. The most recent insider tranaction occured on September, 27th when CAO Jitendra Wadhane bought 2,500 shares worth more than $4,675.00. Insiders at Pyxis Oncology own 8.4% of the company. Learn More about insider trades at Pyxis Oncology.
Information on this page was last updated on 9/27/2023.

Thomas Civik Insider Trading History at Pyxis Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/18/2021	Buy	15,700	$12.74	$200,018.00

Thomas Civik Buying and Selling Activity at Pyxis Oncology

Pyxis Oncology Company Overview

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $4.40

$4.25

$4.42

50 Day Range

MA: $5.12

$3.65

$6.59

2 Week Range

Now: $4.40

$1.35

$6.85

Volume

96,627 shs

Average Volume

780,983 shs

Market Capitalization

$255.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51